Retatrutide: The Triple Agonist Redefining Metabolic Research

What is Retatrutide?

Retatrutide (LY3437943) is a first-in-class triple incretin receptor agonist developed by Eli Lilly and Company. Unlike its predecessors — single-agonist GLP-1 (GLP-1 only) and dual-agonist GLP-2 (GLP-1 + GIP) — Retatrutide simultaneously activates three receptors: GLP-1, GIP, and the glucagon receptor. This triple mechanism represents the most advanced approach to incretin-based metabolic research to date.

The Triple Mechanism of Action

GLP-1 Receptor Activation

• Reduces appetite through hypothalamic signaling and delayed gastric emptying
• Stimulates glucose-dependent insulin secretion from pancreatic beta cells
• Suppresses glucagon release in a glucose-dependent manner

GIP Receptor Activation

• Enhances insulin sensitivity in adipose tissue
• Promotes lipid metabolism and fat oxidation
• Modulates bone metabolism and energy expenditure

Glucagon Receptor Activation — The Key Differentiator

This is what sets Retatrutide apart from all other incretin-based peptides:

• Increased energy expenditure: Glucagon receptor activation directly increases basal metabolic rate through hepatic energy metabolism
• Enhanced lipolysis: Promotes breakdown of stored fat in both subcutaneous and visceral depots
• Hepatic fat reduction: Glucagon signaling drives fatty acid oxidation in the liver, directly targeting hepatic steatosis (fatty liver)
• Thermogenesis: Stimulates brown adipose tissue activation, converting stored energy into heat

The glucagon component is what researchers believe drives Retatrutide’s superior efficacy compared to dual-agonist approaches — it adds a direct energy expenditure pathway on top of the appetite suppression provided by GLP-1 and the metabolic optimization from GIP.

Landmark Clinical Results

Phase 2 Trial (2023)

The Phase 2 study published in the New England Journal of Medicine established Retatrutide as the most potent weight-loss peptide ever tested:

• Participants receiving the highest dose (12 mg) achieved a mean body weight reduction of 24.2% at 48 weeks
• Nearly 100% of participants on the 12 mg dose lost at least 5% of their body weight
• Approximately 26% of participants achieved ≥30% weight loss — a threshold previously only achievable through bariatric surgery
• HbA1c reductions of up to 2.02 percentage points in participants with type 2 diabetes

TRIUMPH-4: The First Successful Phase 3 Trial (December 2025)

In December 2025, Eli Lilly announced the results of TRIUMPH-4, the first Phase 3 clinical trial for Retatrutide, conducted in participants with obesity and knee osteoarthritis:

• 28.7% mean body weight reduction at the 12 mg dose over 68 weeks — translating to an average loss of 71.2 lbs (32.3 kg)
• The 9 mg dose achieved 25.4% weight loss
• Both the 9 mg and 12 mg doses met all primary and secondary endpoints
• WOMAC pain scores (measuring osteoarthritis pain) were reduced by up to 75.8% (4.5 points), demonstrating that weight reduction directly and substantially alleviates joint pain
• Significant improvements in physical function and stiffness measures in the knee joint
• Meaningful reductions in cardiovascular risk factors including blood pressure, lipid profiles, and inflammatory markers

Ongoing Phase 3 Program

Eli Lilly is conducting seven additional Phase 3 trials under the TRIUMPH program, with results expected throughout 2026:

• TRIUMPH-1: Obesity without diabetes
• TRIUMPH-2: Obesity with type 2 diabetes
• TRIUMPH-3: Metabolic-associated steatohepatitis (MASH/NASH)
• TRIUMPH-5: Heart failure with preserved ejection fraction (HFpEF) and obesity
• TRIUMPH-6: Obstructive sleep apnea
• TRIUMPH-7: Chronic kidney disease associated with obesity

Comparative Analysis

Why the Glucagon Component Matters

The addition of glucagon receptor agonism creates a fundamentally different metabolic profile:

Hepatic Fat Clearance

In Phase 2 substudies, Retatrutide demonstrated up to 80-90% reduction in liver fat content measured by MRI-PDFF (proton density fat fraction). This is dramatically higher than either GLP-1 (~40-50%) or GLP-2 (~50-60%), and positions Retatrutide as potentially the most effective pharmacological approach to MASH (metabolic-associated steatohepatitis) ever studied.

Body Composition

Analysis from Phase 2 substudies published in The Lancet Diabetes & Endocrinology showed:

• Significant reductions in both subcutaneous and visceral adipose tissue
• Greater preservation of lean body mass relative to total weight lost compared to GLP-1 agonists alone
• The glucagon component’s thermogenic effect may contribute to preferential fat loss over muscle loss

Metabolic Rate

Unlike GLP-1 agonists (which primarily reduce caloric intake without increasing energy expenditure), Retatrutide’s glucagon component directly increases resting metabolic rate. This dual approach — eating less AND burning more — is hypothesized to drive the superior weight loss outcomes observed in clinical trials.

Safety and Tolerability

The TRIUMPH-4 trial revealed important tolerability data:

• Gastrointestinal events remain the most common adverse effects: nausea, diarrhea, vomiting, and constipation — consistent with the GLP-1 class
• Discontinuation rates due to adverse events were 8.6% for 9 mg and 13.6% for 12 mg (compared to 2.4% placebo), which is higher than some competitors and has prompted discussion about dose optimization strategies
• Most GI effects were mild-to-moderate and occurred primarily during dose escalation
• No new safety signals were identified beyond the established GLP-1/GIP/glucagon class effects

Research Significance

Retatrutide represents a paradigm shift in metabolic peptide research for several reasons:

• First triple agonist to reach Phase 3: Validates the hypothesis that adding glucagon receptor activation to GLP-1/GIP agonism produces superior metabolic outcomes
• Approaching surgical benchmarks: The 28.7% weight loss observed in TRIUMPH-4 begins to rival outcomes seen with Roux-en-Y gastric bypass (30-35% at 2 years)
• Multi-organ metabolic effects: The combination of weight loss, liver fat clearance, and cardiovascular risk factor improvement suggests Retatrutide addresses metabolic disease holistically rather than targeting individual symptoms
• New therapeutic frontiers: The TRIUMPH program is testing Retatrutide across conditions (sleep apnea, CKD, heart failure) that have historically had limited pharmacological options

Available Research Formats

• Lyophilized vials (10mg, 20mg): Standard reconstitution format for subcutaneous research protocols
• Nasal spray (10mg/10ml): Intranasal delivery being studied for improved convenience and compliance

Conclusion

Retatrutide stands as the most advanced metabolic peptide in clinical development. The TRIUMPH-4 results — demonstrating 28.7% weight loss and 75.8% pain reduction in osteoarthritis — validate the triple agonist hypothesis and establish a new benchmark in metabolic research. With seven additional Phase 3 trials ongoing, 2026 will be a defining year for Retatrutide and the future of incretin-based metabolic science.